





# Congo

African Region



Based on 2015 reported data


## I. Epidemiological profile

Population (UN)	2016	%	Parasites and vectors
High transmission (> 1 case per 1000 population)	5,130,000	100	Plasmodium species: <i>P. falciparum</i> (100%), <i>P. vivax</i> (0%)
Low transmission (0-1 cases per 1000 population)	-	-	Major anopheles species: <i>An. gambiae</i> , <i>An. funestus</i> , <i>An. niii</i> , <i>An. moucheti</i>
Malaria-free (0 cases)	-	-	Reported confirmed cases (health facility): 171,847 Estimated cases: 1,049,000 [522,000–1,758,000]
Total	5,126,000	-	Confirmed cases at community level: - Reported deaths: 733 Estimated deaths: 2,000 [1,800–2,300]


## II. Intervention policies and strategies

Intervention	Policies/strategies	Yes/No	Adopted	Antimalarial treatment policy	Medicine	Year adopted					
ITN	ITNs/ LLINs distributed free of charge	Yes	2007	First-line treatment of unconfirmed malaria	AS+AQ	-					
	ITNs/ LLINs distributed to all age groups	Yes	2011	First-line treatment of <i>P. falciparum</i>	AS+AQ	-					
IRS	IRS is recommended	Yes	2007	Treatment failure of <i>P. falciparum</i>	AL	-					
	DDT is authorized for IRS	No	-	Treatment of severe malaria	QN	-					
Larval control	Use of larval control recommended	No	-	Treatment of <i>P. vivax</i>	-	-					
IPT	IPT used to prevent malaria during pregnancy	Yes	2006	Dosage of Primaquine for radical treatment of <i>P. vivax</i>	-	-					
Diagnosis	Patients of all ages should receive diagnostic test	Yes	2014	Type of RDT used	-	P.f only					
	Malaria diagnosis is free of charge in the public sector	No	-								
Treatment	ACT is free of charge for all ages in public sector	No	-	<b>Therapeutic efficacy tests (clinical and parasitological failure, %)</b>							
	The sale of oral artemisinin-based monotherapies (oAMTs)	Is banned	2006	Medicine	Year(s)	Min	Median	Max	Follow-up	No. of studies	Species
	Single dose of primaquine is used as gametocidal medicine for <i>P. falciparum</i>	No	-	AL	2010-2017	0	0	3.6	28 days	5	<i>P. falciparum</i>
	Primaquine is used for radical treatment of <i>P. vivax</i>	No	-	AS+AQ	2010-2017	0	2.4	4	28 days	4	<i>P. falciparum</i>
	G6PD test is a requirement before treatment with primaquine	No	-	<b>Insecticide resistance tests (mosquito mortality, %)</b>							
	Directly observed treatment with primaquine is undertaken	No	-	Insecticide class	Years	Min	Mean	Max	No. of sites	Species	
	System for monitoring adverse reactions to antimalarials exists	No	-	Pyrethroids	2013-2013	0.5	0.8	0.9	1	<i>An. gambiae s.l.</i>	
Surveillance	ACD for case investigation (reactive)	No	-	Organochlorines	2013-2014	0.1	0.6	1	4	<i>An. gambiae s.l.</i>	
	ACD of febrile cases at community level (pro-active)	No	-	Organophosphates	2013-2014	1	1	1	4	<i>An. gambiae s.l.</i>	
	Mass screening is undertaken	No	-	Carbamates	2013-2014	1	1	1	4	<i>An. gambiae s.l.</i>	
	Uncomplicated <i>P. falciparum</i> cases routinely admitted	Yes	-	<b>Government expenditure by intervention in 2016</b>							
	Uncomplicated <i>P. vivax</i> cases routinely admitted	No	-	Pie chart showing expenditure on: Insecticides & spray materials, ITNs, Diagnostic testing, Antimalarial medicines, Monitoring and Evaluation, Human Resources & Technical Assistance, Management and other costs.							
	Foci and case investigation undertaken	-	-	Bar chart showing contribution (\$USm) from 2011 to 2016 by source: Gov. expend., Global Fund, World Bank, USAID/PMI, WHO/UNICEF, Others.							
	Case reporting from private sector is mandatory	No	-	Line and bar chart showing coverage of ITN and IRS from 2005 to 2016. Legend includes: With access to ITN (model), All ages who slept under ITN (survey), With access to ITN (survey), At risk protected with IRS.							


## III. Financing




## Government expenditure by intervention in 2016




## IV. Coverage




## Cases tested and treated in public sector




## V. Impact



## Test positivity



## Confirmed malaria cases per 1000 and ABER



## Malaria admissions and deaths (per 100 000)

